Clinical Research Directory
Browse clinical research sites, groups, and studies.
Gut Microbiome and Metabolic Health Study
Sponsor: RDC Clinical Pty Ltd
Summary
The goal of this clinical trial is to assess whether TRPTI (oleoylethanolamide) can reduce plasma imidazole propionate levels and improve insulin sensitivity and metabolic health in healthy adults aged 18 years and above with BMI 18.5-29.9 kg/m². The main question it aims to answer is does TRPTI reduce plasma imidazole propionate (a gut microbiota-derived metabolite linked to insulin resistance)? Researchers will compare TRPTI 150 mg, TRPTI 300 mg, and placebo in a parallel design to see if TRPTI reduces imidazole propionate levels and improves metabolic health markers compared to placebo. Participants will: * Take 2 capsules of their assigned study product daily for 4 consecutive weeks * Attend 2 clinic visits (at baseline and week 4)
Official title: A Double-blind, Randomised, Placebo-controlled Parallel Study to Assess the Effectiveness of TRPTI (Oleoylethanolamide) Compared to Placebo on Gut Microbiome and Plasma Biomarker Changes in Healthy Adults
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
90
Start Date
2026-03
Completion Date
2027-03
Last Updated
2026-03-09
Healthy Volunteers
Yes
Conditions
Interventions
TRPTI 150mg
Participants will take two capsules daily, for 28 consecutive days. Their daily dose of TRPTI will be 150mg.
TRPTI 300mg
Participants will take two capsules daily, for 28 consecutive days. Their daily dose of TRPTI will be 300mg
Placebo
Participants will take two capsules daily, for 28 consecutive days. Their daily dose of TRPTI will be 0mg
Locations (1)
RDC Clinical
Brisbane, Queensland, Australia